Filter Results:
- Full text PDF available (3)
Publication Year
2008
2019
- This year (9)
- Last 5 years (27)
- Last 10 years (36)
Publication Type
Co-author
Journals and Conferences
Learn More
- Mikko Gynther, Krista Laine, +6 authors Jarkko Rautio
- Journal of medicinal chemistry
- 2008
The blood-brain barrier efficiently controls the entry of drug molecules into the brain. We describe a feasible means to achieve carrier-mediated drug transport into the rat brain via the specific,… (More)
- Lauri Peura, Kalle Malmioja, +4 authors Jarkko Rautio
- Molecular pharmaceutics
- 2011
Central nervous system (CNS) drug delivery is a major challenge in drug development because the blood-brain barrier (BBB) efficiently restricts the entry of drug molecules into the CNS at sufficient… (More)
- Jarkko Rautio, Krista Laine, Mikko Gynther, Jouko E T Savolainen
- The AAPS Journal
- 2008
Central nervous system (CNS) drug delivery remains a major challenge, despite extensive efforts that have been made to develop novel strategies to overcome obstacles. Prodrugs are bioreversible… (More)
- Henna Ylikangas, Kalle Malmioja, +8 authors Antti Poso
- ChemMedChem
- 2014
L-Type amino acid transporter 1 (LAT1) is a transmembrane protein expressed abundantly at the blood-brain barrier (BBB), where it ensures the transport of hydrophobic acids from the blood to the… (More)
- Mikko Gynther, Jarmo Ropponen, +5 authors Jarkko Rautio
- Journal of medicinal chemistry
- 2009
The brain uptake of solutes is efficiently governed by the blood-brain barrier (BBB). The BBB expresses a number of carrier-mediated transport mechanisms, and new knowledge of these BBB transporters… (More)
- Mikko Gynther, Aaro J Jalkanen, +6 authors Jarkko Rautio
- International journal of pharmaceutics
- 2010
The blood-brain barrier (BBB) controls the entry of xenobiotics into the brain. Often the development of central nervous system drugs needs to be terminated because of their poor brain uptake. We… (More)
- Kristiina M Huttunen, Mikko Gynther, Johanna Huttunen, Elena Puris, Julie Ann Spicer, William A. Denny
- Journal of medicinal chemistry
- 2016
The l-type amino acid transporter 1 (LAT1) is a transmembrane protein carrying bulky and neutral amino acids into cells. LAT1 is overexpressed in several types of tumors, and its inhibition can… (More)
- Jesper Tobias Andreasen, Mikko Gynther, Allan Rygaard, Trine Bøgelund, Darryl S Pickering
- Neuroscience Letters
- 2013
Monoamine-based antidepressant drugs increase α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) function and decrease N-methyl-d-aspartate receptor (NMDAR) function. The NMDAR… (More)
- Jarkko Rautio, Mikko Gynther, Krista Laine
- Therapeutic delivery
- 2013
- Mikko Gynther, Darryl S Pickering, Julie Ann Spicer, William A. Denny, Kristiina M Huttunen
- Molecular pharmaceutics
- 2016
We have recently reported that by converting a perforin inhibitor into an l-type amino acid transporter 1 (LAT1)-utilizing prodrug its cellular uptake can be greatly increased. The aim of the present… (More)